Merck & Co., Inc. (MRK) income statement
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 9/30240% above fair value
$143.37−1.09 (-0.75%)
Close on Nov 17, 2026Market cap $353.72BP/E 114.7Yield 2.29%
Merck & Co., Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- 73.0%
- Operating margin
- –
- Net margin
- 4.8%
- Return on equity, FY2025
- 36.9%
Financial strength
- Current ratio
- 1.32
- Debt to equity
- 1.29
- Debt to assets
- 41.5%
- Cash to current liabilities
- 24.7%
Valuation
- P/E ratio
- 114.7
- Price to sales
- 5.31
- Price to book
- 8.44
- Dividend yield
- 2.29%
See a number that looks wrong?